BIOMAT Database Logo BIOMAT Database Logo

Plasma iron status and lipid peroxidation following thrombolytic therapy for acute myocardial infarction. 1998

Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Centre de Cardiologie, CHRU, Dijon, France.

Free radical species have been implicated as important agents involved in myocardial ischemic and reperfusion injuries. Superoxide is capable of mobilizing iron from ferritin and the released iron can cause hydroxyl formation from H2O2. The aim of this study was to evaluate the time-dependent increase in lipid peroxidation assessed by plasma thiobarbituric acid reactive substances (TBARS) and the relationship between lipid-peroxidation and the iron status. Peripheral venous blood samples were obtained from 17 men with acute myocardial infarction (AMI) before thrombolytic treatment (T0) and 1, 2, 3, 4, 8, 12, 16, 20, 24 and 48 hours after commencing fibrinolytic treatment. The concentration of TBARS, the parameters of iron metabolism, serum myoglobin, creatine kinase, and creatine kinase-MB were measured. Early reperfusion was judged by regression of sinus tachycardia (ST) elevation and reduction of chest pain. Recanalization of coronary artery was evaluated by a late coronary angiography 24-96 hours after thrombolysis. After thrombolytic therapy, the TBARS level was raised from 2.98 +/- 0.80 (T0) to 4.57 +/- 1.24 (peak), and decreased to 2.96 +/- 0.40 nmol/mL plasma at T48 (T0 vs peak: P < 0.001, peak vs T48: P < 0.001, T0 vs T48: NS). The mean time of the peak was observed at 9.7 +/- 7.5 hours. The iron increased significantly from 0.67 +/- 0.34 (T0) to 1.15 +/- 0.52 mg/L (peak), and returned to the pre-reperfusion to levels: 0.53 +/- 0.28 UI/L at T48 (TO vs peak: P < 0.001, peak vs T48: P < 0.001, T0 vs T48: NS). The mean time of the peak was observed at 9.4 +/- 7.3 hours. In return, no correlation was found between the increase of plasma creatine-kinase activity, myoglobin and iron or between the biochemical markers and time of fibrinolytic therapy. The results confirmed the importance of the temporal relationship between lipid peroxidation and iron status after thrombolytic therapy. Our results are in agreement with the concept that antioxidant agents used in association with thrombolytic therapy might be useful.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid

Related Publications

Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Lipid peroxidation and antioxidant status following thrombolytic therapy for acute myocardial infarction.
August 1993, European heart journal,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Effect of intravenous nitroglycerin on lipid peroxidation after thrombolytic therapy for acute myocardial infarction.
December 1998, The American journal of cardiology,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Haemarthrosis following thrombolytic therapy for acute myocardial infarction.
March 1997, Injury,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
The state of lipid peroxidation and antioxidants following thrombolytic therapy with rt-PA and streptokinase in acute myocardial infarction.
May 1999, Japanese heart journal,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Iron status and its relationship with lipid peroxidation in patients with acute myocardial infarction.
October 2001, Acta cardiologica,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Systemic embolization following thrombolytic therapy for acute myocardial infarction.
March 1990, Chest,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Spontaneous hemarthrosis following thrombolytic therapy for acute myocardial infarction.
July 1993, International journal of cardiology,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction.
December 1991, Seminars in neurology,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Stress echocardiography following thrombolytic therapy and acute myocardial infarction.
June 1992, American journal of cardiac imaging,
Y Cottin, and J M Doise, and V Maupoil, and M Tannière-Zeller, and F Dalloz, and M Maynadié, and M K Walker, and P Louis, and P M Carli, and J E Wolf, and L Rochette
Thrombolytic therapy for acute myocardial infarction.
August 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Copied contents to your clipboard!